Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* First time liver transplant recipient whose primary pre-transplant diagnosis was chronic hepatitis C genotype 1~* More than 6 months to 10 years post-liver transplant~* Patient did or did not receive treatment for HCV prior to liver transplantation~* Patient must agree to have a liver graft biopsy during the screening period unless they had a biopsy within three months of the screening period (for patients between 6 months and one year post transplant) or within six months of the screening period (for patients who are more than one year post transplant)~* A female patient of childbearing potential and a nonvasectomized male patient who has a female partner of childbearing potential must agree to the use of 2 effective methods of birth control from screening until 6 months (female patient) or 7 months (male patient) after the last dose of ribavirin~Exclusion Criteria:~* Patient is currently infected or co-infected with HCV of another genotype than genotype 1~* Patient received treatment for hepatitis C following liver transplantation~* Patient has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis C~* Patient with human immunodeficiency virus or hepatitis B virus co-infection~* Patient with active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma or hepatocellular carcinoma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Telaprevir+Peg-IFN-alfa-2a+Ribavirin (Type: EXPERIMENTAL): Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).